Introduction: While the liraglutide effect and
Only patients who were persistent on their index treatment during a 180-day post-index period were included.
Follow-up A1C
assessments were based on available laboratory data within 45 days before or after the 6-month post-index point in time. Diabetes-related pharmacy costs over the 6-month post-index period were captured and included costs for both the index drugs and concomitant diabetes medications.
Results: 234 LIRA and 182 EXEN patients were identified for the analysis. The adjusted predicted diabetes-related pharmacy costs per patient over the 6-month post-index period were higher for LIRA compared to EXEN ($2,002 [1] . Most of the costs are attributable to the care of individuals with type 2 diabetes mellitus (T2DM) and treating the complications of T2DM, while only 12% of total health care costs relate to antidiabetic medications and supplies.
To reduce the costs of diabetes, preventing the development of diabetes complications through glycemic control is imperative [1, 2] .
Consequently, glycemic control is an essential component of the effective management of T2DM [3] and its associated health care costs [2] .
The American Diabetes Association (ADA) recommends a glycated hemoglobin A1C (A1C) goal of \7.0% in most patients to reduce the incidence of microvascular complications [3] . documented by randomized clinical trials, meta-analyses, and systematic reviews [4] [5] [6] [7] [8] [9] [10] [11] .
The LEAD-6 (liraglutide effect and action in diabetes) clinical trial (NCT00518882) compared the efficacy and safety of LIRA once daily to EXEN twice daily in adult patients with T2DM inadequately controlled on metformin, a sulfonylurea, or both [9] . LIRA provided significantly greater reductions in A1C and higher rates of A1C goal achievement compared to EXEN. A second study reported greater A1C reductions, higher rates of A1C goal achievement, and greater weight loss with LIRA once daily vs. EXEN once weekly [10] . 
Statistical Analysis
All patient demographic and clinical characteristics as well as diabetes-related pharmacy costs were descriptively reported. 
RESULTS

Demographic and Clinical Characteristics
There were few significant differences when comparing the clinical characteristics between LIRA and EXEN patients ( P\0.0001) and more EXEN patients had claims for hypoglycemia in the pre-index period compared to LIRA patients (2.2% vs. 0.0%; P = 0.04). The total average outpatient pharmacy costs in the pre-index period were higher for patients initiating LIRA compared to EXEN ($704 vs. $567; P = 0.02) ( Table 1) .
Descriptive A1C and Cost Outcomes:
Unadjusted Results
Prior to adjusting for confounding factors, a significantly greater proportion of LIRA patients achieved an A1C value of \7% as compared to EXEN patients (64.5% vs. 54.4%; P = 0.04) ( Table 3 ). The difference in A1C from baseline to 6 months post-index was also significantly greater for LIRA patients compared to EXEN patients (-0.99% vs. -0.68%; P = 0.02). Over the 6-month post-index period, descriptive unadjusted total diabetes-related pharmacy costs per patient were similar between the two groups ($1,993 vs. $1,924; P = 0.376) ( Table 4) .
Adjusted A1C and Cost Outcomes: Multivariable Models
The factors associated with achieving A1C\7%
were estimated using a multivariable logistic regression model (Table 5) . EXEN patients were 43.5% less likely to reach A1C\7% compared to LIRA patients (OR = 0.565; P = 0.015). Plan type as well as certain pre-and post-index concomitant medications had a significant impact on the likelihood of reaching A1C\7%.
The factors associated with total diabetesrelated pharmacy costs over the 6-month postindex period were identified via a GLM model.
After controlling for covariates such as age, gender, baseline A1C level, comorbidity history and concomitant medication use, diabetesrelated pharmacy costs per patient were lower for EXEN patients compared to LIRA patients (parameter estimate = -$203.1; P = 0.0002) ( Table 6 ). As for the logistic regression model, plan type as well as certain pre-and post-index concomitant medications had a significant impact on the estimated total diabetes-related pharmacy costs in this GLM model.
Cost per Patient to Achieve A1C < 7%
The cost per patient to achieve A1C\7% portrays a simplistic and transparent way of assessing the short-term cost-effectiveness of the treatment alternatives. The adjusted predicted diabetes-related pharmacy costs per patient were (Fig. 1) . In terms of cost per patient successfully achieving A1C\7%, this translates into a lower cost of control for LIRA compared to EXEN ($3,108 ± $779 vs. $3,354 ± $936; P\0.0001) (Fig. 2) .
DISCUSSION
This study is among the first to evaluate the real-world cost-effectiveness of treating patients to A1C\7% with LIRA once daily and EXEN twice daily using a real-world administrative claims dataset. In this analysis, the adjusted predicted diabetes-related pharmacy costs per patient were higher with LIRA than with EXEN ($2,002 vs. $1,799, P\0.001). However, as a greater proportion of patients on LIRA reached A1C\7% compared to patients on EXEN (64.4% vs. 53.6%, P\0.05), total diabetesrelated pharmacy costs per successfully treated patient were lower with LIRA than with EXEN ($3,108 vs. $3,354; P\0.0001). In fact, the A1C reductions observed in this study are consistent with the findings reported in LEAD-6 [9] .
Still, this retrospective study differs from clinical trials in that randomized clinical trials contain strict inclusion and exclusion criteria and pre-defined concomitant antidiabetic medication use. For example, this study included patients with baseline A1C\7.0%, patients who would have been excluded from clinical trials of LIRA. Consequently, the mean A1C in this study was slightly lower (7.8%) than in LEAD-6 (8.2% with LIRA and 8.1% with EXEN). This difference likely explains, at least in part, the difference in the proportion of patients achieving A1C\7.0% between this study and those reported in LEAD-6 [9] . In this study, 65% of patients on LIRA and 54% on EXEN achieved A1C\7.0% (P\0.05) (Fig. 1) . In LEAD-6, 54% on LIRA and 43% on EXEN achieved A1C\7.0% (P = 0.0015). [10] . In this 26-week trial, A1C reductions were -1.48% with LIRA and -1.28% with EXEN once weekly (P = 0.02) respectively) compared to those in our study (7.8% for both LIRA and EXEN). Furthermore, the patients who were randomized to LIRA in DURATION-6 had a forced titration to LIRA 1.8 mg, whereas the drug dose was not ascertained for this analysis.
While the clinical superiority of LIRA compared to EXEN has been well documented in a clinical trial setting, our findings contextualize the relative efficacy of these agents with the per-patient costs associated with A1C goal achievement in clinical practice. Real-world evidence has become increasingly important as a decision-making tool for policymakers and health care providers as they struggle to control increasing [12, 13] . Presumably, a metric such as cost per patient to A1C goal in diabetes care could be considered when evaluating provider performance under an ACO, making the findings of our study particularly relevant.
Studies that have examined the cost implications of improving glucose management have reported that the glycemic control costs are modest compared to total diabetes-related health expenditures [1, 14] .
Other studies have evaluated the comparative costs and cost-effectiveness of glucose-lowering agents in T2DM, including the use of incretin therapies, both in the USA [15, 16] and in Europe [17, 18] . In the US retrospective cohort study by Pelletier and colleagues, patients receiving exenatide twice daily and liraglutide once daily had similar total 6-month follow-up (inpatient and outpatient) costs ($6,688 vs. $7,346) [15] . However, patients receiving exenatide had significantly lower mean pharmacy costs ($2,925 vs. $3,272, P\0.001). Importantly, the study did not evaluate or relate these findings to outcomes in A1C or other indicators of glycemic control, such as microvascular complications or other outcomes associated with reductions in A1C.
In a retrospective chart audit of patients in the United Kingdom who received LIRA, EXEN, or a DPP-4 inhibitor (sitagliptin, saxagliptin, or vildagliptin), for a median of 48 weeks, significantly greater reductions in A1C (all P\0.05) were seen with LIRA (-1.22%) than both EXEN (-0.71%), and the DPP-4 inhibitors (-0.66%) [17] . Estimated life-years gained per patient were 0.12 with LIRA, 0.08 with EXEN, and 0.07 with DPP-4 inhibitors, yielding a cost per quality-adjusted life year of £16,505, £16,648, and £20,661, respectively [17] .
One recent report evaluated the short-term cost-effectiveness of LIRA vs. sitagliptin based on data from a randomized controlled trial of patients who failed to achieve A1C goals on metformin therapy [19, 20] . The simplistic and transparent short-term cost-effectiveness methodology applied in our real-world study of the cost of control follows the approach taken by Langer and colleagues in relating cost to treatment success [19] .
Limitations
These results must be viewed with the typical limitations associated with studies based on administrative claims data. The correspondence between pharmacy submission of claims and patients' receipt and consumption of the medication was assumed and not directly measured. However, prior work suggests that medication exposure can be accurately derived from pharmacy claims [21, 22] . The study also assumed that all information needed for cohort stratification was present and similar across the cohorts of interest.
Of note, this study excluded any patients that had evidence of insulin use in either the pre-or post-index periods and cohorts were limited to consist of patients being persistent on their index therapy for a 6-month post-index period. Insulin users were excluded to remove any of the potentially additive or synergistic glucose-lowering effects of such a combination regimen, thereby focusing exclusively on the ability of LIRA and EXEN to improve glycemic control.
